Search for:
CytomX
Search for:
About
Overview
Mission, Vision, Values
Executive Team
Board of Directors
Scientific Advisory Board
Contact Us
Probody Therapeutics
Our Probody Approach
How Probody Therapeutics Work
A Versatile Platform
Scientific Publications & Presentations
Pipeline
Advancing our Pipeline
Lead Candidates
Clinical Trials
Access for HCPs/Patients
Partners
Opportunities
Current Partners
Investors & News
Corporate Profile
Press Releases
Events & Presentations
Scientific Publications
Corporate Governance
Stock Information
Financial & Filings
Analyst Coverage
Investor Resources
Culture & Careers
Overview
Mission-Driven Culture
Current Openings
Total Rewards Program
Corporate Amenities
Home
Terms of use
Privacy notices
Disclaimer for X
Menu
Transforming lives with safer, more effective therapies.
Varsetatug masetecan (CX-2051): Unlocking EpCAM as a Cancer Target via a Masked EPCAM-Directed Topo1 ADC
Sean McCarthy, D.Phil., CEO and Chairman